The evidence record / preclinical to Phase 3
PT-141 Research: The Bremelanotide Evidence Record
From the founding melanocortin pharmacology to the RECONNECT Phase 3 trials and the FDA label — every finding logged to its source.
The short version
The PT-141 research record is unusually complete for a peptide discussed online: it runs from animal pharmacology in the early 2000s to two large human trials and an FDA approval in 2019 [7][10]. The early work showed PT-141 acts in the brain to drive sexual behavior in rats and monkeys [1] and the appetitive (wanting) side of behavior in female rats [2]. The big human trials (called RECONNECT) then showed a real but modest benefit for desire in women with HSDD [3], which held up over a year [4].
Newer work fills in the picture: brain-imaging studies show where the effect happens [5], and a 2025 animal study refines which brain circuits are and aren't involved [6]. This page walks the record in order — preclinical, then the human trials, then the label, then the newest data — and cites every finding so you can check it on PT-141 references.
Founding pharmacology: a central mechanism
PT-141 entered the literature as a melanocortin agonist for sexual dysfunction. The foundational paper established that PT-141, a synthetic alpha-MSH analogue, agonizes MC3R/MC4R expressed mainly in the CNS; systemic administration produced penile erections in rats and nonhuman primates, activated hypothalamic neurons (increased c-Fos), and produced rapid dose-dependent erectile activity in men with erectile dysfunction [1].
The female-behavior work followed. In female rats, PT-141 selectively stimulated appetitive solicitational sexual behaviors without affecting lordosis, pacing, or general motor activity — the first reported pharmacological agent acting specifically on appetitive female sexual behavior [2]. Together these studies fixed PT-141 as a central, not peripheral, actor.
The RECONNECT Phase 3 trials
The pivotal evidence is two identical Phase 3 randomized controlled trials, RECONNECT (n=1267 premenopausal women with HSDD) [3]. Bremelanotide 1.75 mg subcutaneous as-needed produced a statistically significant improvement in sexual desire (integrated FSFI-desire +0.35, P<.001) and a reduction in desire-related distress (FSDS-DAO item 13 −0.33, P<.001) versus placebo over 24 weeks; both coprimary endpoints were met in both trials [3]. The most common adverse events were nausea, flushing, and headache [3].
Durability came from the 52-week open-label extension (684 women): no new safety signals, sustained desire improvement, with nausea (40.4%), flushing (20.6%), and headache (12.0%) the most common drug-related treatment-emergent events [4].
Direct neuroimaging and a refining 2025 study
The mechanism has direct human-brain support. A randomized, double-blind, placebo-controlled crossover fMRI study of 31 premenopausal women with HSDD found MC4R agonism significantly increased sexual desire for up to 24 hours and altered task-based brain processing — enhanced amygdala–insula functional connectivity and cerebellar/supplementary-motor activity — in response to erotic stimuli [5].
A 2025 study in female Syrian hamsters refined the circuit map: MC3R/MC4R mRNA was concentrated in ventral-tegmental-area dopamine neurons, but neither low- nor high-dose bremelanotide changed melanocortin-receptor mRNA in the mesolimbic dopamine system, and bremelanotide did not enhance sexual reward (conditioned place preference) — suggesting it does not act on the VTA–nucleus-accumbens reward circuit [6]. A negative, clarifying result of this kind is part of an honest record.
The regulatory and review record
The authoritative dose, pharmacokinetics, and warnings come from the US prescribing information for bremelanotide injection: the HSDD indication, 1.75 mg subcutaneous as-needed (max one dose/24 h, no more than eight doses/month), terminal half-life ~2.7 h, and a transient blood-pressure warning with a hypertension/CVD contraindication [7]. The first-approval review documents the June 2019 milestone and development history [10], and a 2020 analysis of FDA-approved peptide and oligonucleotide therapeutics situates bremelanotide within that year's strong run of peptide approvals [9]. An early development profile records PT-141's intranasal ED origins and planned Phase III [8], a narrative HSDD review positions melanocortins as excitatory neuromodulators of desire distinct from serotonergic mechanisms [11], and a forensic study confirms bremelanotide in seized black-market samples — a reminder that unregulated supply circulates outside all of this [13].